B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
RNA
Atrium TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA IND clearance, the launch of the first ATR 1072 Phase 1/2 trial, and continued BMS milestones materially improve Atrium's development profile. Successful first-patient enrollment and eventual proof-of-concept could support substantial upside.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +39.5.
What can break
ATR 1072 has not yet produced human efficacy data; safety, tolerability, pharmacokinetics, and dose selection remain unproven.
Momentum
57
Value
59
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $25.00 · Bear $7.50Analysis 2026-09-10; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-10 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $25.00
Why
Momentum57 · Δ7d -16.6
Value59 · Δ7d 0.0
Sentiment100 · Δ7d +39.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +39.5.
Contradictions & invalidation
- • ATR 1072 has not yet produced human efficacy data; safety, tolerability, pharmacokinetics, and dose selection remain unproven.
- • Coverage is thin, peers are loose, and analyst revisions or consensus-surprise data are unavailable.
- • Atrium remains an early clinical biotech with no demonstrated human efficacy.
Catalyst clock
2026-09-30
Second Bristol Myers Squibb milestone
Lead driver: Sentiment · See AI snapshot
Momentum
57
9% active weight
Current posture
7d trendSoftening
Δ7d
-16.6
Δ21d
+51.5
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.0
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+39.5
Δ21d
+33.8
Why this grade
Composite grade A. Momentum 56.6 / Value 58.8 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-10. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$221.69M
Beta
0.93
Shares Out
17.11M
P/E (TTM) · Derived
-4.5
P/S (TTM)
520.38
P/FCF (TTM) · Derived
-2.86
Rev YoY
-21.9%
EPS YoY
+56.7%
Gross Margin
-
Op Margin
-2934.9%
Net Debt
$3.67M
Current Ratio
8.73
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data